Treatment with Trastuzumab Beyond Progression
| Autor: | Gunter von Minckwitz, Cristina Pirvulescu |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Antibody-dependent cell-mediated cytotoxicity
Oncology medicine.medical_specialty business.industry Lapatinib medicine.disease Metastatic breast cancer Blockade Capecitabine Breast cancer Trastuzumab Internal medicine Medicine Pertuzumab skin and connective tissue diseases business neoplasms medicine.drug |
| Zdroj: | Drugs for HER-2-positive Breast Cancer ISBN: 9783034600934 |
| DOI: | 10.1007/978-3-0346-0094-1_4 |
| Popis: | Trastuzumab is the first antibody that has shown clinical activity in patients with HER-2-positive breast cancer. The mechanism of action is not fully understood; however, antibody-derived cellular cytotoxicity (ADCC) is considered to explain important peculiarities of its clinical activity such as treatment beyond progression. Based on early pre-clinical data, trastuzumab was used beyond progression since the start of its clinical use. Initially evidence to use trastuzumab beyond progression came only from observational studies, which might have been biased by the unknown decision criteria for or against continuation of trastuzumab. Only recently, the randomised GBG 26 study demonstrated that capecitabine and continuing trastuzumab beyond progression achieved a higher response rate and longer progression-free survival than capecitabine alone. Supportive evidence came from studies combining trastuzumab with lapatinib or pertuzumab in trastuzumab pre-treated patients, showing better results than the same treatment without trastuzumab. A blockade of HER-2 throughout all stages of Her-2-positive breast cancer should therefore be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|